Literature DB >> 12408784

Variceal Bleeding.

Mark W. Russo1.   

Abstract

Primary prophylaxis: Patients with cirrhosis who have esophageal varices but who have never had a bleeding episode may be treated medically or endoscopically. Without treatment, approximately 30% of cirrhotic patients with varices bleed and this risk is reduced by approximately 50% with therapy. Medical therapy includes nonselective beta blockers with or without nitrates. Compliance and side effects limit efficacy. Primary prophylaxis with endoscopic sclerotherapy is not warranted because of evidence suggesting that complications outweigh benefits. Studies of endoscopic therapy with ligation (endoscopic banding) demonstrate that in select patients (those with large varices), endoscopic banding may reduce the risk of first bleeding episode when compared with propranolol. Patients with large varices may benefit from a combination of banding with nonselective beta blockers. Secondary prophylaxis: After an initial variceal bleed, the risk of a second bleed is high and therapy is warranted to reduce the risk of rebleeding. The options are similar to those for primary prophylaxis, and in addition to medical and endoscopic therapy, transjugular intrahepatic portosystemic shunts (TIPS) and surgical shunts are therapeutic options. The combination of endoscopic therapy with medical therapy is the initial approach to prevent variceal rebleeding. Endoscopic banding is preferred to sclerotherapy because banding is associated with lower bleeding rates and fewer complications. TIPS is useful in cases refractory to endoscopic therapy or in uncontrolled variceal hemorrhage. Surgical shunts are typically reserved for patients in whom TIPS cannot be performed for technical reasons or for well-compensated cirrhotic patients. Acute variceal bleeding: Acute bleeding from esophageal varices requires an endoscopic evaluation and therapeutic intervention. Technically, endoscopic banding may not be possible because of limited visualization from bleeding and sclerotherapy is used because it is easier to perform in this setting. A continuous intravenous drip of octreotide should be initiated if variceal bleeding is suspected. If variceal bleeding cannot be controlled, then a Minnesota tube or Sengstaken-Blakemore tube should be placed by someone with experience. TIPS is effective rescue therapy for controlling acute variceal hemorrhage in circumstances when other methods fail.

Entities:  

Year:  2002        PMID: 12408784     DOI: 10.1007/s11938-002-0035-9

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  18 in total

1.  Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding.

Authors:  M W Russo; S L Zacks; R S Sandler; R S Brown
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

2.  Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. A randomized, single-blind, multicenter clinical trial.

Authors: 
Journal:  N Engl J Med       Date:  1991-06-20       Impact factor: 91.245

3.  The economic impact of esophageal variceal hemorrhage: cost-effectiveness implications of endoscopic therapy.

Authors:  I M Gralnek; D M Jensen; T O Kovacs; R Jutabha; G A Machicado; J Gornbein; J King; S Cheng; M E Jensen
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Endoscopic sclerotherapy versus variceal ligation in the long-term management of patients with cirrhosis after variceal bleeding. A prospective randomized study.

Authors:  A Avgerinos; A Armonis; S Manolakopoulos; G Poulianos; G Rekoumis; A Sgourou; P Gouma; S Raptis
Journal:  J Hepatol       Date:  1997-05       Impact factor: 25.083

5.  Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt.

Authors:  Mark W Russo; Paul F Jacques; Matthew Mauro; Pat Odell; Robert S Brown
Journal:  Liver Transpl       Date:  2002-03       Impact factor: 5.799

6.  Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP)

Authors:  C Merkel; R Marin; E Enzo; C Donada; G Cavallarin; P Torboli; P Amodio; G Sebastianelli; D Sacerdoti; M Felder; C Mazzaro; P Beltrame; A Gatta
Journal:  Lancet       Date:  1996 Dec 21-28       Impact factor: 79.321

7.  Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis.

Authors:  J C Teran; T F Imperiale; K D Mullen; A S Tavill; A J McCullough
Journal:  Gastroenterology       Date:  1997-02       Impact factor: 22.682

Review 8.  Portal hypertension management.

Authors:  J Terblanche
Journal:  Surg Endosc       Date:  1993 Nov-Dec       Impact factor: 4.584

9.  Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study.

Authors:  G Idéo; G Bellati; E Fesce; D Grimoldi
Journal:  Hepatology       Date:  1988 Jan-Feb       Impact factor: 17.425

10.  Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients.

Authors:  S K Sarin; D Lahoti; S P Saxena; N S Murthy; U K Makwana
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

View more
  1 in total

Review 1.  Management of Variceal Hemorrhage.

Authors:  Yan Li; Chun Qing Zhang
Journal:  Gastroenterology Res       Date:  2009-01-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.